MGMT promoter methylation and glioblastoma prognosis: A systematic review and meta-analysis

Archives of Medical Research

Volumn 44, Issue 4, 2013, Pages 281-290

  Chen, Yang ^a   Hu, Fulan ^b   Zhou, Yiheng ^c   Chen, Wangyang ^b   Shao, Hongying ^b   Zhang, Ying ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Dalian Center of Disease Control and Prevention   (China)

Author keywords

Glioblastoma prognosis; Meta analysis; MGMT; Promoter methylation

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CANCER SURVIVAL; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; META ANALYSIS; METHYLATION; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SYSTEMATIC REVIEW;

BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DNA METHYLATION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMANS; METHYLATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84879724501     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.04.004     Document Type: Article

References (56)

1. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
2. Ohgaki H., Dessen P., Jourde B., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004, 64:6892-6899.
3. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
4. Sonoda Y., Yokosawa M., Saito R., et al. O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 2010, 15:352-358.
5. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4:296-307.
6. Kaina B., Christmann M., Naumann S., et al. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007, 6:1079-1099.
7. Friedman H.S., McLendon R.E., Kerby T., et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998, 16:3851-3857.
8. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
9. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
10. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004, 10:4933-4938.
11. Chinot O.L., Barrie M., Fuentes S., et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007, 25:1470-1475.
12. Olson R.A., Brastianos P.K., Palma D.A. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol 2011, 105:325-335.
13. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2197.
14. Clarke J.L., Iwamoto F.M., Sul J., et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009, 27:3861-3867.
15. Costa B.M., Caeiro C., Guimaraes I., et al. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep 2010, 23:1655-1662.
16. Dunn J., Baborie A., Alam F., et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009, 101:124-131.
17. Felsberg J., Rapp M., Loeser S., et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009, 15:6683-6693.
18. Metellus P., Coulibaly B., Nanni I., et al. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 2009, 115:4783-4794.
19. Rivera A.L., Pelloski C.E., Gilbert M.R., et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010, 12:116-121.
20. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
21. Ochsenbein A.F., Schubert A.D., Vassella E., et al. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas. J Neurooncol 2011, 103:343-351.
22. Brell M. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005, 11:5167-5174.
23. Etcheverry A., Aubry M., Tayrac M.D.E., et al. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics 2010, 11:701.
24. Felsberg J., Thon N., Eigenbrod S., et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer Suppl 2011, 129:659-670.
25. Kang S.H., Park K.J., Kim C.Y., et al. O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. J Neurooncol 2010, 101:477-486.
26. Sonoda Y., Kumabe T., Watanabe M., et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 2009, 151:1349-1358.
27. Thon N., Eigenbrod S., Grasbon-Frodl E.M., et al. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. J Neurol Neurosurg Psychiatry 2010, 82:441-446.
28. van den Bent M.J., Dubbink H.J., Sanson M., et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009, 27:5881-5886.
29. Wemmert S., Bettscheider M., Alt S., et al. p15 promoter methylation: a novel prognostic marker in glioblastoma patients. Int J Oncol 2009, 34:1743-1748.
30. Wick W., Hartmann C., Engel C., et al. NOA-04 Randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27:5874-5880.
31. Karayan-Tapon L., Quillien V., Guilhot J., et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 2009, 97:311-322.
32. Glas M., Happold C., Rieger J., et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009, 27:1257-1261.
33. Weller M., Felsberg J., Hartmann C., et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009, 27:5743-5750.
34. Park C.K., Park S.H., Lee S.H., et al. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology 2009, 29:443-449.
35. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
36. Kamiryo T., Tada K., Shiraishi S., et al. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acidmethyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 2004, 54:349-357.
37. Cao V.T., Jung T.Y., Jung S., et al. The correlation and prognostic significance of MGMT promoter methylation and MGMY protein in glioblastomas. Neurosurgery 2009, 65:866-875.
38. Watanabe T., Katayama Y., Komine C., et al. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer Suppl 2005, 113:581-587.
39. Eoli M., Menghi F., Bruzzone M.G., et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 2007, 13:2606-2613.
40. Gerstner E.R., Yip S., Wang D.L., et al. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology 2009, 73:1509-1510.
41. Zawlik I., Vaccarella S., Kita D., et al. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 2009, 32:21-29.
42. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
43. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
44. Steels E., Paesmans M., Berghmans T., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001, 18:705-719.
45. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
46. Fleiss J.L. The statistical basis of meta-analysis. Stat Methods Med Res 1993, 2:121-145.
47. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
48. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
49. Schaich M., Kestel L., Pfirrmann M., et al. A MDR1 (ABCB1) genesingle nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 2009, 20:175-181.
50. Esteller M., Hamilton S.R., Burger P.C., et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59:793-797.
51. Bobola M.S., Berger M.S., Silber J.R. Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. Mol Carcinog 1995, 13:81-88.
52. Preusser M., Charles Janzer R., Felsberg J., et al. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008, 18:520-532.
53. Preusser M., Elezi L., Hainfellner J.A. Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 2008, 27:388-390.
54. Preusser M. MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 2009, 24:511-518.
55. Mason S., McDonald K. MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry. J Cancer Res Clin Oncol 2012, 138:1789-1797.
56. Berghoff A.S., Preusser M. Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients-yes, but how?. Clin Neuropathol 2012, 31:405-408.